Work

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.802.802

Authors: Ian Flinn, Yasuhiro Oki, Manish Patel, Steven M. Horwitz, Francine M. Foss, Jennifer Sweeney, Kerstin Allen, Mark Douglas, Lori Steelman, Joi Dunbar, Howard M. Stern, Patrick Kelly, Brad Kahl

Institutions: Sarah Cannon, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Yale University, Infinity Pharmaceuticals (United States), University of Wisconsin–Madison

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1476088316

FWCI: 8.409

Cites:

Cited by: 48

Related to: 10